{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "69-year-old man with a 2.3 pack-year smoking history was diagnosed with right lung cancer of the lower lobe (clinical stage IA, T1bN0M0).",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "2.3 pack-year smoking history"
            }
          ],
          "diagnoses": [
            {
              "code": "C0024117",
              "label": "Lung Cancer",
              "status": "active",
              "location": "right lower lobe"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Patient underwent right lower lobectomy and lymph node resection.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Lobectomy, Lower Lobe of Right Lung",
              "approach": "open",
              "date": null,
              "location": "Right Lung",
              "performed_by": null,
              "outcome": null
            },
            {
              "name": "Lymph Node Resection",
              "approach": "open",
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Postoperative pathological diagnosis was invasive adenocarcinoma, papillary predominant (mixed subtype: papillary 55%, acinar 25%, lepidic 20%), and the tumor size was 2.5\u2009\u00d7\u20091.5 cm with pulmonary metastasis; pathological stage was IIIA, T3(pm1)N2M0. The EGFR of the tumor showed exon 19 deletion.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0242394",
              "label": "Adenocarcinoma, Invasive",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C0020622",
              "label": "Pulmonary Metastasis",
              "status": "active",
              "onset_date": null
            }
          ],
          "imaging": [
            {
              "type": "C0024112",
              "body_part": "C0034088",
              "modality": null,
              "finding": "Tumor size was 2.5 x 1.5 cm",
              "impression": null,
              "date": null
            }
          ],
          "procedures": [
            {
              "name": "Exon 19 deletion analysis",
              "approach": null,
              "date": null,
              "location": "tumor",
              "performed_by": null,
              "outcome": "positive"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Patient received four cycles of cisplatin and pemetrexed as postoperative adjuvant treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0008833",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "postoperative adjuvant treatment"
            },
            {
              "drug": "C0698788",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "postoperative adjuvant treatment"
            }
          ],
          "procedures": [
            {
              "name": "adjuvant treatment",
              "approach": null,
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Follow-up CT/MRI 7 months after surgery revealed multiple pulmonary metastases and brain metastases.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Pulmonary CT",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "multiple pulmonary metastases",
              "date": "7 months after surgery"
            },
            {
              "type": "Brain MRI",
              "body_part": "Brain",
              "modality": "MRI",
              "finding": "brain metastases",
              "date": "7 months after surgery"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Patient underwent stereotactic radiotherapy for brain metastasis.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Stereotactic Radiotherapy",
              "approach": "other",
              "date": null,
              "location": "Brain",
              "performed_by": null,
              "outcome": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "Brain Metastasis",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Afatinib was administered at a dose of 40 mg/day.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Afatinib",
              "dosage": "40 mg/day",
              "frequency": "daily",
              "modality": "oral"
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "1 month after the initiation of afatinib treatment, chest CT revealed marked shrinkage of the metastatic lesions.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Metastatic Lesion",
              "body_part": "Chest",
              "modality": "CT",
              "finding": "Marked shrinkage",
              "date": null
            }
          ],
          "medications": [
            {
              "drug": "Afatinib",
              "start_date": null,
              "end_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Patient continued to receive afatinib, despite the presentation of grade 2 diarrhea and rash.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0984100",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0012542",
              "label": "Diarrhea",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C0034572",
              "label": "Rash",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "28 months after surgery (21 months after the initiation of afatinib treatment), brain MRI revealed leptomeningeal enhancement and patient was diagnosed with leptomeningeal carcinomatosis (LM), which was cytologically proven by a cerebrospinal fluid (CSF) analysis.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Magnetic resonance imaging of brain",
              "body_part": "Brain",
              "modality": "MRI",
              "finding": "leptomeningeal enhancement",
              "date": null
            }
          ],
          "diagnoses": [
            {
              "code": "C79.31",
              "label": "Leptomeningeal carcinomatosis",
              "status": "active",
              "onset_date": null
            }
          ],
          "labs": [
            {
              "test": "Cerebrospinal Fluid Analysis",
              "value": "positive",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "medications": [
            {
              "drug": "Afatinib",
              "dosage": null,
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Tumor marker levels increased compared to preoperative levels: CEA 3.1 to 23.0 ng/mL, CYFRA 1.6 to 2.8 ng/mL. Patient was asymptomatic with no progression of pulmonary metastasis. Plasma cell free DNA and CSF samples were negative for EGFR T790M.",
        "clinical_data": {
          "labs": [
            {
              "test": "C0007540",
              "value": "23.0",
              "unit": "ng/mL",
              "flag": "abnormal",
              "reference_range": ">3.1",
              "timestamp": null
            },
            {
              "test": "CYFRA 21-1 Antigen",
              "value": "2.8",
              "unit": "ng/mL",
              "flag": "abnormal",
              "reference_range": ">1.6",
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "EGFR",
              "label": "Epidermal Growth Factor Receptor",
              "status": "suspected",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "Patient was treated with bevacizumab (15 mg/kg every 3 weeks) and erlotinib (150 mg/day).",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1308694",
              "dosage": "15 mg/kg",
              "frequency": "every 3 weeks",
              "modality": "IV",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1634939",
              "dosage": "150 mg/day",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Follow-up MRI at 2 months showed markedly decreased leptomeningeal enhancement and declined tumor marker levels: CFA 23.0 to 15.2, CYFRA 2.8 to 2.5.",
        "clinical_data": {
          "imaging": [
            {
              "type": "MRI",
              "body_part": "meninges",
              "modality": "MRI",
              "finding": "markedly decreased leptomeningeal enhancement",
              "date": "unknown"
            }
          ],
          "labs": [
            {
              "test": "CFA",
              "value": "15.2",
              "unit": "unknown",
              "timestamp": "unknown"
            },
            {
              "test": "CYFRA",
              "value": "2.5",
              "unit": "unknown",
              "timestamp": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N14",
      "label": "Step 14",
      "customData": {
        "node_id": "N",
        "node_step_index": 13,
        "content": "Disease control was maintained for 4 months from the start of bevacizumab and erlotinib treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1307179",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1272485",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N15",
      "label": "Step 15",
      "customData": {
        "node_id": "O",
        "node_step_index": 14,
        "content": "Dose reduction of erlotinib was required because of grade 3 AST/ALT elevation.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1634990",
              "dosage": "reduced",
              "indication": "cancer"
            }
          ],
          "labs": [
            {
              "test": "C0151829",
              "flag": "abnormal",
              "comment": "grade 3 elevation"
            },
            {
              "test": "C0002791",
              "flag": "abnormal",
              "comment": "grade 3 elevation"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient underwent right lower lobectomy and lymph node resection."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Postoperative pathological diagnosis was invasive adenocarcinoma, papillary predominant (mixed subtype: papillary 55%, acinar 25%, lepidic 20%), and the tumor size was 2.5\u2009\u00d7\u20091.5 cm with pulmonary metastasis; pathological stage was IIIA, T3(pm1)N2M0. The EGFR of the tumor showed exon 19 deletion."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Patient received four cycles of cisplatin and pemetrexed as postoperative adjuvant treatment.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008833",
            "C0698788"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Follow-up CT/MRI 7 months after surgery revealed multiple pulmonary metastases and brain metastases."
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Patient underwent stereotactic radiotherapy for brain metastasis."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Afatinib was administered at a dose of 40 mg/day.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "Afatinib"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "1 month after the initiation of afatinib treatment, chest CT revealed marked shrinkage of the metastatic lesions."
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Patient continued to receive afatinib, despite the presentation of grade 2 diarrhea and rash."
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "28 months after surgery (21 months after the initiation of afatinib treatment), brain MRI revealed leptomeningeal enhancement and patient was diagnosed with leptomeningeal carcinomatosis (LM), which was cytologically proven by a cerebrospinal fluid (CSF) analysis."
      }
    },
    {
      "from": "N10",
      "to": "N11",
      "data": {
        "edge_id": "J_to_K",
        "branch_flag": true,
        "content": "Tumor marker levels increased compared to preoperative levels: CEA 3.1 to 23.0 ng/mL, CYFRA 1.6 to 2.8 ng/mL. Patient was asymptomatic with no progression of pulmonary metastasis. Plasma cell free DNA and CSF samples were negative for EGFR T790M."
      }
    },
    {
      "from": "N11",
      "to": "N12",
      "data": {
        "edge_id": "K_to_L",
        "branch_flag": true,
        "content": "Patient was treated with bevacizumab (15 mg/kg every 3 weeks) and erlotinib (150 mg/day).",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1308694",
            "C1634939"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N12",
      "to": "N13",
      "data": {
        "edge_id": "L_to_M",
        "branch_flag": true,
        "content": "Follow-up MRI"
      }
    }
  ]
}